Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | SELE | P16581 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25220812 | 0.81 | LMNA (0.43) | KDM4CL3MBTL1RAB9AKMT2AMEN1 | |
| SCHEMBL15728455 | 0.78 | KDM4C (0.35) | KDM4CL3MBTL1NPC1RAB9AICAM1 | |
| SCHEMBL7243739 | 0.76 | KDM4C (0.39) | KDM4CL3MBTL1NPC1RAB9AICAM1 | |
| SCHEMBL12126157 | 0.75 | KDM4C (0.41) | KDM4CL3MBTL1NPC1RAB9AICAM1 | |
| SCHEMBL15244567 | 0.70 | KDM4C (0.37) | KDM4CL3MBTL1NPC1RAB9AICAM1 | |
| SCHEMBL2830733 | 0.69 | ICAM1 (0.44) | KDM4CL3MBTL1NPC1RAB9AICAM1 | |
| SCHEMBL17888696 | 0.69 | KDM4C (0.36) | KDM4CL3MBTL1NPC1RAB9AICAM1 | |
| SCHEMBL23662562 | 0.68 | DHFR (0.43) | KDM4CL3MBTL1NPC1RAB9AICAM1 | |
| SCHEMBL10565976 | 0.68 | KDM4C (0.42) | KDM4CL3MBTL1NPC1RAB9AICAM1 | |
| SCHEMBL29447793 | 0.67 | KDM4C (0.40) | KDM4CL3MBTL1NPC1RAB9AICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464077-B2 | Nitrogen-containing aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | KDM4C 443/4885L3MBTL1 1663/4885NPC1 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.